Cost/effectiveness evaluation of three fixed combinations of acetaminophen and opioids in the management of acute pain in Colombia

Cristancho, R. Alfonso; Vecino, Andres I.; Misas, Juan Diego

doi:10.1016/j.rcae.2014.06.004

Cited by 1 publication

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their study, Cristancho et al (2013) found that an FDC of acetaminophen and codeine (AC) had lower cost and was more effective in reducing pain within the first hours after administration versus an acetaminophen and hydrocodone (AH) FDC or an acetaminophen plus tramadol (AT) FDC [265]. The costs/numbers needed to treat for each formulation were $1816 Colombian pesos/2.2 for AC, $4772 Colombian peso/2.3 for AH, and $5342/ 2.6 for AT.…”

Section: Painmentioning

confidence: 99%

See 1 more Smart Citation

Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries

Godman

McCabe

Leong

2020

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower-and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country's essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed.

show abstract

Section: Painmentioning

confidence: 99%

“…The costs/numbers needed to treat for each formulation were $1816 Colombian pesos/2.2 for AC, $4772 Colombian peso/2.3 for AH, and $5342/ 2.6 for AT. Using AC as the comparator, the ICER for AT from a payer's perspective was $8790 Colombian pesos and $29,640 Colombian pesos for AH [265].…”

Section: Painmentioning

confidence: 99%